title: Angiotensin-converting enzyme inhibition as a therapeutic principle in Bartter's syndrome.
abstract: The effect of captopril has been investigated in four patients with Bartter's syndrome treated for 12 weeks. Baseline biochemistry showed normal serum aldosterone (mean 347 pmol.l-1) and a mean serum renin of 217 mU-l-1, and a considerable increase in serum renin during captopril treatment. Serum aldosterone decreased gradually during the study period to about half its initial value. The patients presented with a mean serum potassium of 2.5 mmol.l-1, which rose to 3.4 mmol.l-1 on captopril. Lymphocytes showed a substantial captopril-induced increase in intracellular sodium (from 15 to 22.5 mmol.l-1 on average), but no change in the potassium content. Captopril was well-tolerated. It may be an alternative to potassium-sparing diuretics for maintaining normal serum potassium levels in patients with Bartter's syndrome.
authors.affiliation: Department of Clinical Chemistry, Odense University Hospital, Denmark.
authors.forename: P
authors.initials: P
authors.lastname: Jest
authors.forename: K E
authors.initials: KE
authors.lastname: Pedersen
authors.forename: N A
authors.initials: NA
authors.lastname: Klitgaard
authors.forename: N
authors.initials: N
authors.lastname: Thomsen
authors.forename: K
authors.initials: K
authors.lastname: Kjaer
authors.forename: E
authors.initials: E
authors.lastname: Simonsen
mesh_terms: D000328:Adult; D000450:Aldosterone / Q000097:blood; D001477:Bartter Syndrome / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy*; D002216:Captopril / Q000008:administration & dosage / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D006760:Hospitalization; D006801:Humans; D008297:Male; D011188:Potassium / Q000008:administration & dosage / Q000097:blood; D012083:Renin / Q000097:blood; D012964:Sodium / Q000097:blood
chemical_list: D000450:Aldosterone; D002216:Captopril; D012964:Sodium; D012083:Renin; D011188:Potassium